Virosomal adjuvanted antigen delivery systems

Expert Review of Vaccines

Volumn 2, Issue 2, 2003, Pages 189-196

  Moser, Christian ^a   Metcalfe, Ian C ^a   Viret, Jean François ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

Adjuvant; Humoral and cellular immunity; Licensed virosomal adjuvanted vaccines; Tolerability; Vaccine; Virosome

Indexed keywords

ADJUVANT; ALUMINUM; ANTIGEN; DIPHTHERIA VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NUCLEIC ACID; PEPTIDE; TETANUS TOXOID; TRIPLE VACCINE; UNCLASSIFIED DRUG; VACCINE; VIROSOME;

ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; EDEMA; HUMAN; IMMUNOGENICITY; LICENSING; NONHUMAN; PAIN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVIEW; SKIN INDURATION;

ADJUVANTS, IMMUNOLOGIC; HEPATITIS A VACCINES; HUMANS; INFLUENZA VACCINES; VACCINES, COMBINED; VACCINES, VIROSOME; VIROSOMES;

EID: 0037847495     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.2.189     Document Type: Review

References (45)

1. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv Rev. 32(3), 155-172 (1998).
2. Théry C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol. 13(1), 45-51 (2001). Comprehensive review of antigen presentation mechanisms in APCs.
3. Sigal LJ, Crotty S, Andino R, Rock KL Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398(6722), 77-80 (1999). Experimental evidence for MHC I presentation of exogenous antigen (cross-priming.
4. Mischler R, Metcalfe IC. Inflexal® V a trivalent virosome subunit influenza vaccine: production. Vaccine 20(Suppl. 5), B17-B23 (2002). Formulation of virosomes at industrial scale.
5. +-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. 271, 13417-13421 (1996).
6. Han X, Bushweller JH, Cafiso DS, Tamm LK. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza haemagglutinin. Nat. Struc. Biol. 8, 715-720 (2001).
7. Schoen P, Leserman L, Wilschut J. Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions. FEBS Lett. 390(3), 315-318 (1996).
8. Gunther-Ausborn S, Schoen P, Bartoldus I, Wilschut J, Stegmann T Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity. J. Virol. 74(6), 2714-2720 (2000).
9. Hernandez LD, Hoffman LR, Wolfsberg TG, White JM. Virus-cell and cell-cell fusion. Annu. Rev. Cell. Dev. Biol. 12, 627-661 (1996).
10. +)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. J. Biol. Chem. 269, 18353-18358 (1994).
11. Kim CU, Chen X, Mendel DB. Neuraminidase inhibitors as anti-influenza virus agents. Antivir. Chem. Chemother. 10(4), 141-154 (1999).
12. Mengiardi B, Berger R, Just M, Gluck R. Virosomes as carriers for combined vaccines. Vaccine 13(14), 1306-1315 (1995). Clinical evaluation of virosomal combination vaccines, coformulated by crosslinking and adsorption.
13. Cusi MG, Zurbriggen R, Correale P et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine 20(29-30), 3436-3442 (2002).
14. Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20(17-18), 2287-2295 (2002). Mechanism of cytoplasmatic antigen delivery by virosomes - importance of HA compound.
15. Zurbfiggen R, Gluck R. Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17(11-12), 1301-1305 (1999).
16. Zurbriggen R, Novak-Hofer I, Seelig A, Gluck R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 39(1), 3-18 (2000). Analytical methods for the characterization of virosomal vaccines.
17. Poltl-Frank F, Zurbriggen R, Helg A et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin. Exp. Immunol. 117(3), 496-503 (1999).
18. Fehr T, Bachmann MF, Bucher E et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J. Exp. Med. 185(10), 1721-1723 (1997).
19. Bungener L, Huckriede A, Wilschut J, Daemen T Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci. Rep. 22(2), 323-338 (2002). Comparison of virosomes to other lipid-based delivery/adjuvant systems.
20. Bungener L, Idema J, ter Veer W, Huckriede A, Daemen T, Wilschut J. Virosomes in vaccine development: induction of cytocoxic T lymphocyte activity with virosome-encapsulated protein antigens. J. Liposome Res. 12(1-2), 155-163 (2002).
21. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18(14), 1327-1333 (2000). Evidence that the induction of cellular immune response depends on the presence of fusion-active HA in the virosomes.
22. Rott O, Charreire J, Mignon-Godefroy K, Cash E. B cell superstimulatory influenza virus activates peritoneal B cells. J. Immunol. 155(1), 134-142 (1995).
23. 2+-independent mechanism. J. Immunol. 154(5), 2092-2103 (1995).
24. Wiedermann G, Kundi M, Ambrosch F, Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop. 69(2), 121-125 (1998).
25. Mayorga O, Egger M, Zellmeyer M, Glueck R, Herzog C, Froesner G. Efficacy of virosome formulated hepatitis A vaccine in an endemic region in Nicaragua: a randomized placebo-controlled trial. Presented at 37th ICAAC, Toronto, Canada, H4 (1997) (Abstract).
26. Dagan R, Amir J, Mijalovsky A et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J. 19(11), 1045-1052 (2000).
27. Loutan L, Bovier P, Althaus B, Glueck R. Inactivated virosome hepatitis A vaccine. Lancet 343, 322-324 (1994).
28. Loutan L. Use of a virosome formulated hepatitis A vaccine in adults > 50 years of age. Clin. Microbiol. Infect. 6(Suppl. 1), WeP305 (2000) (Abstract and poster).
29. Riedemann S, Reinhardt G, Froesner GG, Glück R, Herzog C. Universal seroconversion and low rate of side effects after one dose of the new Hepatitis A vaccine Epaxal, even when given to children less than 2 years of age. Schweiz Wochenschr. 126(Suppl. 71/I), 46S (1996).
30. Holzer BR, Hatz C, Schmidt-Sissolak D, Glück R, Althaus B, Egger M. Immunogenidty and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 14(10), 982-986 (1996). Clinicial trial comparing alum-adjuvanted and virosomal vaccines.
31. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol 68(4), 489-493 (2002).
32. Cryz SJ, Que JU, Gluck R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 14(14), 1381-1383 (1996).
33. Glück R, Cryz J Jr. IRIV Vaccine Delivery. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon IGS (Eds). Marcel Dekker Inc., NY, USA, 247-252 (1997).
34. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344(8916), 160-163 (1994).
35. Conne P, Gauthey L, Vernet P et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15,1675-1679 (1997).
36. Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano). 13(1), 38-43 (2001).
37. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R; Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19(25-26), 3472-3475 (2001).
38. Cusi MG, Zurbriggen R, Valassina M et al. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology 277(1), 111-118 (2000). Proof of principle for mucosal DNA delivery by virosomes.
39. Correale P, Cusi MG, Sabatino M et al. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer. 37(16), 2097-2103 (2001). DNA-encoded antigen delivery by virosomes induces systemic cellular immune response against a cancer antigen.
40. Waelti E, Wegmann N, Schwaninger R et al. Targeting her-2/neu with antitat Neu virosomes for cancer therapy. Cancer Res. 62(2), 437-444 (2002). Targeted virosomes for delivery of an encapsulated cytotoxic drug to cancer cells in vivo.
41. Ebbert GB, Mascolo ED, Six HR. Overview of vaccine manufacturing and quality assurance. In: Vaccines (Third Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders Company, PA, USA, 40-46 (1999).
42. Ada G. The immunology of vaccination. In: Vaccines (Third Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders Company, PA, USA, 28-39 (1999).
43. Hunziker IP, Grabscheid B, Zurbriggen R, Gluck R, Pichler WJ, Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int. Immunol. 14(6), 615-626 (2002).
44. Moreno R, Jiang L, Moehle K et al. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2(11), 838-843 (2001).
45. Hunziker IP, Zurbriggen R, Glueck R et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38(6), 475-484 (2001).